RxDoctor Payments Data

Denny Tate, MD

Internal Medicine · Graham, NCNPI 1033180823

Payments from drug & device makers

$1,619in general payments, 2019–2025

Across 120 payments — averaging $13.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$452
  • Lilly USA, LLC$367
  • AstraZeneca$296
  • Merck$149
  • Pfizer$128
  • Amarin Pharma, Inc.$75
  • plus $152 from 5 others

What the payments were for

  • Food & beverage$1,58498%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,619 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,260
Medicare patients
82
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$97,691
OzempicSemaglutide27$38,226
JanuviaSitagliptin Phosphate36$35,191
FarxigaDapagliflozin Propanediol19$24,223
EliquisApixaban23$21,932
RexultiBrexpiprazole14$20,268
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,262
Tresiba Flextouch U-100Insulin Degludec14$10,119
SymbicortBudesonide/Formoterol Fumarate34$9,020
XareltoRivaroxaban15$7,422
Tresiba Flextouch U-200Insulin Degludec12$6,935
NexiumEsomeprazole Magnesium12$6,649
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,290
Sumatriptan Succinate15$6,192
TradjentaLinagliptin12$5,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$17$103,038115 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium$296$52,15585 claims
Novo NordiskOzempic$452$38,22627 claims
MerckJanuvia$149$35,19136 claims
PfizerEliquis, Paxlovid$128$23,33235 claims
Otsuka America Pharmaceutical, Inc.Rexulti$13$20,26814 claims
Johnson & JohnsonXarelto$18$7,42215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Graham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →